BioCurex Completes Tens of Millions RMB Angel Financing to Accelerate Biosynthesis Product Portfolio

VCBeat (WeChat ID: vcbeat) recently learned that synthetic biology company BaiKuiRui Bio announced the completion of its angel round financing, amounting to tens of millions of RMB.Led by Shanghai Volcanic Stone Capital, with participation from Tianjin Beiyang Haitang Fund and Shanghai Huixin Kangcheng Limited Partnership.The proceeds from this round of financing will be primarily used for the production of biosynthetic targeted bactericidal proteins and functional peptides, accelerating product deployment in the fields of efficacy-based skin health, pet gut health, and rare metabolic disorders. The company also plans to establish a pilot-scale production base, recruit top talent, and build a market expansion team.

For gaining recognition from the capital markets,Founder of Bai Kuirui Biotechstated: “We extend our gratitude to Volcanic Stone, Beiyang Haitang, and Huixin Kangcheng for their recognition of our team. BaiKuiRui is a biotechnology company driven by core technological innovation. Over the next two to three years, we will leverage our platforms for precise protein design and protein molecular machines to continuously innovate and develop a pipeline of protein and peptide products with diverse functionalities. These products will target therapeutic applications in skin health, pet health, and rare metabolic disorders, thereby creating greater value for human health.”

BaiKuiRui Biotechnology, established in 2019 and headquartered at the incubator of the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, within the Tianjin Airport Economic Area, is dedicated to applying synthetic biology technologies for efficient biosynthesis in pharmaceuticals. Leveraging a full-chain synthetic biology platform based on precise protein design and protein molecular machine technologies, the company aims to achieve innovative, efficient, and green manufacturing of biopharmaceuticals and biomaterials.

The company’s founding team comprises biological scientists and PhDs from top Australian universities, as well as entrepreneurs with extensive industry experience. The team has accumulated profound expertise in interdisciplinary fields, including synthetic biology, protein engineering, artificial intelligence, bioinformatics, and chemical engineering. By establishing a technology platform for precise protein design and protein molecular machines, BaiKuiRui Bio focuses on areas such as efficacy-based skincare, rare metabolic disorders, and pet gut health treatments. Leveraging synthetic biology techniques like gene editing, the company develops targeted therapies against harmful bacteria or toxins that adversely affect human health.

Since its inception, BaiKuiRui Bio has been committed to building a technology platform for precise protein design and protein molecular machines. By integrating biological big data, machine learning, and rational design, the company develops powerful protein components. Building on this foundation, it performs directed evolution of protein molecules to further enhance their performance. Leveraging an intelligent, automated, high-throughput screening system combined with efficient gene-editing technologies, BaiKuiRui Bio constructs protein machines with strong synergistic effects. This approach rapidly establishes metabolic synthesis pathways within cells, enabling the design and development of highly efficient cell factories and significantly boosting synthesis efficiency.

Guided by this synthetic biology development paradigm, BaiKuiRui Bio has modularized the biosynthetic production process, creating “plug-and-play” biological parts that enable efficient construction of metabolic pathways for target products in chassis cell factories. This approach paves the way for rapid design of drug synthesis routes and the development of super biocatalytic enzymes. The BaiKuiRui team can rapidly produce high-value-added products tailored to diverse application scenarios, including targeted bactericidal proteins as antibiotic alternatives, functional peptides, engineered functional proteins, and medical-grade enzymes for intestinal delivery.

For the investment in Baikirui Biotechnology, the lead investorZhang Suyang, Founding Partner of Volcanic StoneSummarized from four aspects:

First, over the past two decades, the digitization of life and the biologization of digital information have advanced the development of synthetic biology.

Second, synthetic biology is not a new concept. It is defined as the engineering-based modification of living entities (such as cells) or the de novo construction of biological systems to aid humans in disease treatment, product manufacturing, and environmental remediation. In recent years, the emergence of new disciplines and the advancement of multidisciplinary technologies have accelerated the digitization of life sciences, propelling synthetic biology into a new stage of development.

Third, due to the characteristics of synthetic biology, many future materials and substances will be developed using synthetic biology approaches, with their applications and products increasingly utilized in healthcare, agriculture, chemicals, energy, consumer goods, food and beverage, and other sectors.

Fourth, we are optimistic about the transformative potential and systematic investment opportunities in synthetic biology. The BaiKuiRui team possesses extensive experience in gene recombination, directed protein evolution, gene editing, and the integration of biological big data with machine learning. Leveraging the team’s years of industry accumulation, they demonstrate strong business development capabilities. We believe the company will create greater value in the application of synthetic biology in the future.

Liu Yi, Founding Partner of Beiyang Haitang and Chairman of Andon HealthIt was also stated: “Tianjin University is at the forefront of scientific research in chemical engineering and synthetic biology within China. As the Tianjin University Alumni Fund, we invested in BaiKuirui Biology, an alumni-founded enterprise, due to our optimism about its broad application prospects and significant market potential in the field of synthetic biology. The essence of synthetic biology lies in harnessing cells to produce desired substances for humanity, achieving directed, efficient, and large-scale material processing and transformation. Synthetic biology holds extensive application prospects in fields such as biopharmaceuticals, bio-based chemical synthesis, biomaterials, bioenergy, modern agriculture, and environmental governance.”

“The founding team of Bai Kuirui has accumulated nearly 20 years of technical expertise and industry resources in the fields of protein design and engineering as well as synthetic biology, forming a team with distinct technological and market advantages. Bai Kuirui demonstrates strong commercialization capabilities and has identified suitable entry points for monetization. Compared to other domestic synthetic biology companies, it has taken the lead in commercial implementation, with projects already launched and revenue generated. We are very optimistic about the company’s development prospects.”

Gu Wen, Founding Partner of Huixin Kangchengstated, “By tracking the early-stage entrepreneurial journeys of leading scientists in the industry and participating in investments, we uphold the philosophy of leveraging technology to serve society and respecting science, walking alongside exceptional individuals. We firmly believe that synthetic biology will experience rapid growth over the next decade, transforming traditional production methods and creating a better life. Meanwhile, we highly recognize BaiKuiRui’s core team for its ‘scientist + entrepreneur’ model and its substantial technological accumulation in the field of synthetic biology, and we look forward to the company achieving outstanding performance.”

Volcanic Stone Investment was established in 2016, dedicated to identifying, investing in, and serving high-growth-potential startups in China’s pan-intelligent technology and healthcare sectors. We provide sustained value-added services and grow alongside our portfolio companies. Currently, Volcanic Stone Investment manages assets exceeding RMB 3 billion through dual-currency funds (RMB and USD). Our fund managers have collaborated closely for many years, accumulating over 60 years of combined experience in investment and corporate management, along with deep industry resources. Volcanic Stone Investment aims to harness explosive growth energy and serve as the cornerstone of entrepreneurial success.

The Beiyang Haitang Venture Capital Fund was proposed and initiated in 2018 at the Second Tianjin University Alumni Innovation and Entrepreneurship New Year Forum by more than ten prominent alumni, including Liu Yi, President of the Tianjin University Tianjin Alumni Association and Chairman of Andon Health; Ma Ruren, Founder of Ren’ai Group; Li Haiping, Founder and Chairman of Reagen; Wei Hongkun, Chairman of Tianchuang Capital; Yang Xiaofeng, Chairman of Manwei Group; Su Zhen, Founder of Leyu Technology; Wang Renda, Director and CTO of Andon Health; and He Yongjun, Chairman of Ruiyi Jinrong.

Beiyang Haitang Fund boasts a lean and experienced management team composed of Tianjin University alumni, focusing on investments in next-generation information technology, high-end equipment manufacturing, new energy and advanced materials, biopharmaceuticals, and other sectors. Since its establishment over two years ago, the fund has closely adhered to its mission of being “the first partner on the entrepreneurial journey of alumni,” striving to build an innovation and entrepreneurship ecosystem for Tianjin University alumni and promote the formation of a “Stanford + Silicon Valley” model at the university. Upholding the core values of “helping others succeed to achieve one’s own success” and “deep thinking and innovative practice,” the fund has successively invested in hard-tech projects founded by Tianjin University alumni, including Yunyao Aerospace, Hualai Technology, Huaxin Intelligence, Boer Technology, E-Sight, Yipu Optoelectronics, Prism Space, Qingying Medical, and Baikuirui Biology.

Huixin Kangcheng is a private equity partnership founded by like-minded senior pharmaceutical experts, focusing on early-stage investments in breakthrough biotechnologies. It is committed to funding innovative research and application development of these technologies in healthcare, bio-based materials, agricultural technology, environmental protection, and other fields, thereby sharing a better life.